Skip to content

ADMA Biologics

US · ADMA #2705 by market cap Listed 1970
13.17 -0.17 -1.27%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    Cantor Fitzgerald Downgrades ADMA Biologics(ADMA.US) to Hold Rating, Maintains Target Price $30
    Market Newswire · 2026/3/26
  • Company notice
    ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.
    SEC · 2026/3/11
  • Rating change
    Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/2/26
  • Company notice
    ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.
    SEC · 2026/4/4
  • Rating change
    Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $21
    Market Newswire · 2026/4/21
  • Rating change
    Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $17
    Market Newswire · 2026/7/15
  • Company notice
    ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.
    SEC · 2026/2/24
  • Rating change
    Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $24
    Market Newswire · 2026/4/14
  • CCORF Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $19
    Market Newswire · 2026/11/5
  • Company notice
    4: ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Officer Kestenberg-Messina Kaitlin M.
    SEC · 2026/7/29
  • Rating change
    Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Cuts Target Price to $20
    Market Newswire · 2026/5/7
  • CCORF Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $18
    Market Newswire · 2026/8/6
  • Rating change
    Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Hold Rating, Cuts Target Price to $12
    Market Newswire · 2026/8/6
  • Company notice
    ADMA Biologics | 4: Statement of changes in beneficial ownership of securities-Director Guiheen Lawrence P.
    SEC · 2026/3/18
  • ADMA Biologics Q3 Adj. EPS $0.23 Beats $0.20 Estimate, Sales $141.102M Beat $138.190M Estimate
    Benzinga · 2026/11/5
  • Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Hold Rating, Raises Target Price to $13
    Market Newswire · 2026/11/5
  • Rating change
    Raymond James Initiates ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $21
    Market Newswire · 2026/6/10
  • Rating change
    CCORF Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $21
    Market Newswire · 2026/5/5
  • Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $18
    Market Newswire · 2026/11/5
  • Rating change
    Cantor Fitzgerald Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $30
    Market Newswire · 2025/11/6
  • Rating change
    Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Announces Target Price $35
    Market Newswire · 2025/5/9
  • Rating change
    Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Maintains Target Price $32
    Market Newswire · 2025/8/18
  • ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate
    Benzinga · 2026/8/6
  • Rating change
    Raymond James Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $32
    Market Newswire · 2025/5/9

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

ADMA Biologics discussion 0 comments

Add a comment